Heat waves vs. tumors: new combo therapy for breast cancer
NCT ID NCT05889390
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a non-invasive heat therapy called modulated electro-hyperthermia (mEHT) to standard chemotherapy can shrink tumors more effectively in women with HER2-negative breast cancer. About 71 participants with stage II-III disease will receive chemo with or without mEHT before surgery. The main goal is to see if the combination reduces tumor size more than chemo alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
modulated electro-hyperthermia (mEHT) via Oncotherm EHY-2030 device
What this could lead to
If it works, this could improve tumor shrinkage before surgery, potentially leading to better outcomes for HER2-negative breast cancer patients.
What could go wrong
This is a mid-stage trial with only 71 participants, so results may not apply broadly. The added benefit of mEHT is unproven, and there may be side effects from the device or chemo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University
Budapest, Budapest, 1083, Hungary